人脑胶质瘤MGMT和TopoⅡ基因的表达对其化疗敏感性的影响观察

doi:10.3969/j.issn.1000-8535.2020.05.002

摘要/Abstract

摘要： 目的分析人脑胶质瘤组织中O6—甲基鸟嘌呤—DNA甲基转移酶(MGMT)、DNA拓扑异构酶Ⅱ(TopoⅡ)基因的表达情况及其对化疗敏感性的影响。方法收集医院2012年4月—2018年6月期间进行开颅手术切除的新鲜人脑胶质瘤标本80例和同期经颅脑手术治疗的脑外伤或脑出血内减压切除的正常脑组织30例。采用免疫组化法检测两种标本中MGMT和TopoⅡ基因表达情况,并通过脑胶质瘤U251和U87细胞培养、体外药物(替莫唑胺)干预、Transwell体外侵袭实验分析其对化疗敏感性的影响。结果胶质瘤标本、正常脑组织MGMT和TopoⅡ基因表达程度分布比较差异均有统计学意义(P＜0.05),且二者MGMT基因阳性表达率分别为63.75%、3.33%,TopoⅡ基因阳性表达率分别为55.00%、0.00%,差异有统计学意义(P＜0.05)。MGMT、TopoⅡ基因均在细胞核显示为阳性染色。体外药物干预的实验组、未进行药物干预的阴性对照组干预前U251、U87细胞穿膜细胞计数比较无统计学意义(P＞0.05),但干预后实验组U251、U87细胞穿膜细胞计数高于阴性对照组(P＜0.05),干预后实验组U251、U87细胞有更强的侵袭力。结论 MGMT和TopoⅡ基因在人脑胶质瘤标本中阳性表达率高,且可能参与促进脑胶质瘤细胞侵袭,影响肿瘤化疗敏感性。

关键词: 人脑胶质瘤, MGMT基因, TopoⅡ基因, 表达, 化疗敏感性

Abstract: Objective To analyze the expression of O6-methylguanine-DNA methyltransferase (MGMT) and DNA topoisomerase II (Topo II) genes in human brain gliomas and its influence on the chemosensitivity. Methods A total of 80 fresh human brain glioma specimens resected by craniotomy and 30 normal brain tissues resected by craniocerebral operation for traumatic brain injury or decompression for cerebral hemorrhage during the period from April 2012 to June 2017 were collected. The expression of MGMT and Topo II genes in the two kinds of specimens was detected by immunohistochemical method, and the influence on chemosensitivity was analyzed through brain glioma U251 and U87 cell culture, in vitro drug (temozolomide) intervention and Transwell invasion in vitro. Results There was a significant difference in the expression of MGMT and Topo II genes in glioma specimens and normal brain tissues (P<0.05). The positive expression rates of MGMT gene in the two kinds of specimens were 63.75% and 3.33% respectively while the positive expression rates of Topo II gene were 55.00% and 0.00%, respectively (P<0.05). Both of MGMT and Topo II genes were displayed in the nucleus as positive staining. There was no significant difference in transmembrane cell count of U251 and U87 cells between the experimental group given drug intervention in vitro and negative control group without drug intervention before the intervention (P>0.05). However, the transmembrane cell count of U251 and U87 cells in the experimental group after intervention was higher than that in the negative control group (P<0.05). After intervetion, U251 and U87 cells were with stronger invasiveness in the experimental group. Conclusion The positive expression rates of MGMT and Topo II genes are high in human brain glioma specimens. They may be involved in promoting glioma cell invasion, affecting tumor chemosensitivity.

Key words: Human brain glioma, MGMT gene, Topo II gene, Expression, Chemosensitivity

陈颖东, 宋清宇. 人脑胶质瘤MGMT和TopoⅡ基因的表达对其化疗敏感性的影响观察[J]. 广州医药, 2020, 51(5): 5-8.

CHEN Yingdong, SONG Qingyu. The expression of MGMT and Topo II genes in human brain gliomas and its influence on the chemosensitivity[J]. Guangzhou Medical Journal, 2020, 51(5): 5-8.

参考文献

[1] 周广洲, 靳峰. 脑胶质瘤免疫学特点及其免疫治疗的研究进展[J]. 中国微侵袭神经外科杂志, 2016, 21(11):523-525.
[2] 姚志刚, 王辉, 李加美,等. 不同病理分级星形胶质细胞肿瘤临床特点分析[J]. 山东医药, 2017, 57(23):48-51.
[3] 聂亮琴, 周菊英, 王利利,等. FTO基因对人脑胶质瘤A172细胞放射敏感性的影响及其机制[J]. 中华放射医学与防护杂志, 2015, 35(4):252-256.
[4] 王鹏, 张剑宁, 陈金辉,等. Survivin对体外培养胶质瘤细胞U251替莫唑胺敏感性的影响[J]. 中华神经外科疾病研究杂志, 2016, 15(4):317-320.
[5] 杨洁, 袁江伟, 郭威,等. MGMT蛋白表达对脑恶性胶质瘤切除术后化疗方案的影响[J]. 广东医学, 2015, 22(11):1722-1725.
[6] LOUIS D N, OHGAKI H, WIESTLER O D, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2):97-109.
[7] 王超, 刘建雄. 外泌体在脑胶质瘤诊断与治疗的研究进展[J]. 中国微侵袭神经外科杂志, 2017, 22(2):94-96.
[8] 王文雯. 卡莫司汀植入剂治疗脑胶质瘤的研究进展[J]. 中国肿瘤临床与康复, 2015, 22(2):254-256.
[9] 崔勇, 林靖, 王麒,等. 胶质瘤U87细胞中AKT2基因表达对化疗药物替尼泊苷敏感性的影响[J]. 中国微侵袭神经外科杂志, 2013, 18(11):511-513.
[10] HE W, LIU R, YANG S H, et al. Chemotherapeutic effect of Tamoxifen on Temozolomide-resistant gliomas[J]. AntiCancer Drugs, 2015, 26(3):293-300.
[11] 杜希越, 薛晓英, 盖晓惠,等. 脑胶质瘤分子标志物IDH1R132突变、MGMT和Ki-67与病理分级及预后关系的研究[J]. 安徽医科大学学报, 2017, 52(3):417-421.
[12] 柴其翔, 韦四喜, 王娅婷,等. 调控血红素加氧酶-1诱导K562A02细胞增殖、凋亡及耐药机制研究[J]. 重庆医学, 2016, 45(6):727-730.
[13] 帅萍. 乳腺癌组织中HER2和TopoⅡα的表达及其临床意义[J]. 中南大学学报(医学版), 2016, 41(11):1143-1147.
[14] 秦晋辉, 李军涛. PI3K/Akt信号传导通路在替莫唑胺诱导脑胶质瘤细胞耐药中的作用研究[J]. 临床和实验医学杂志, 2016, 15(2):118-121.
[15] ZACHER A, KAULICH K, STEPANOW S, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel[J]. Brain Pathol, 2017, 27(2):146.
[16] 刘平, 何永生. 脑胶质瘤MGMT和Topo-Ⅱα的表达与肿瘤体外药敏相关性研究[J]. 实用医院临床杂志, 2013, 10(5):42-46.
[17] HOLMES J A, PAULSSON A K, PAGE B R, et al. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design[J]. J Neuro Oncol, 2015, 124(3):447-453.
[18] 吕雨虹, 陈庆, 赵娟,等. 转染白细胞介素18基因通过下调多药耐药基因表达增强顺铂对C6胶质瘤细胞毒作用[J]. 中国现代医学杂志, 2016, 26(10):20-24.
[19] 亓旭晨, 王义荣, 郭振涛,等. 拓扑异构酶Ⅱ对人脑胶质瘤多药耐药性的逆转作用[J]. 中华实验外科杂志, 2013, 30(2):290-292.
[20] 蔡晓君, 韩丽娟, 韦平. 姜黄素抑制MGMT基因表达增强恶性胶质瘤对替莫唑胺化疗的敏感性[J]. 国际肿瘤学杂志, 2016, 43(8):565-569.
[21] STECHISHIN O D, LUCHMAN H A, RUAN Y, et al. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells[J]. Neuro Oncol, 2013, 15(2):198-207.